SESIP Paves the Way for IoT Manufacturers to Meet New European Cybersecurity Rules
12.12.2024 09:00:00 CET | Business Wire | Press release
GlobalPlatform’s SESIP methodology (EN 17927) offers a streamlined, cost-effective security framework for connected devices and components to conform to the EU’s new Cyber Resilience Act
GlobalPlatform is calling for manufacturers of connected devices and components to adopt its “Security Evaluation Standard for IoT Platforms” (SESIP) methodology to demonstrate conformance with the European Union’s new Cyber Resilience Act (CRA), which comes into force this month. The CRA aims to strengthen and harmonize cybersecurity across the EU by creating a new legal framework for all products that connect to the internet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211681976/en/

(Graphic: Business Wire)
The enactment of the CRA puts into place mandatory cybersecurity rules that span the entire lifecycle of a digital product sold in the EU. The CRA was published in the Official Journal of the European Union last month and becomes law on December 11, 2024. Product manufacturers will have 36 months to fully comply with the legislation. The Act will eventually require all relevant products to comply with the rules in order to obtain the CE marking, a mandatory market requirement for issuing products in Europe.
As an internationally recognized standard for IoT security evaluation, SESIP is key to meeting the requirements mandated by the CRA. It provides manufacturers with a proven methodology for conducting security evaluations of software and hardware components across their products and supply chains. SESIP is recognized as a standard by CENELEC, the European Standardization Organization, as EN 17927. It also aligns with many other legislation and vertical certification schemes around the world, including the Cyber Trust Mark in the US.
The methodology is being used to certify components, platforms, and modules from a range of companies and is supported by a growing ecosystem of security providers, certification bodies (CBs), security laboratories, and other stakeholders. GlobalPlatform continues to support the growth and governance of the SESIP ecosystem. SGS Brightsight has recently been accredited as a SESIP CB following approval from the Spanish national accreditation body (ENAC), becoming the second SESIP CB after TrustCB.
“Industry support for SESIP is building at this critical juncture for IoT manufacturers operating in Europe,” said Gil Bernabeu, CTO of GlobalPlatform. “The Cyber Resilience Act is vital to protecting consumers and businesses by embedding security features into the heart of the connected devices we use every day, providing a cybersecurity framework that spans the design, development, and maintenance of digital products.
“However, this landmark legislation presents a range of compliance challenges for manufacturers of connected devices and the components used in these products,” continued Bernabeu. “SESIP simplifies conformity with the new regulations by providing a unified framework for comprehensive security evaluation, reducing cost, risk, and time to market. We look forward to expanding the SESIP ecosystem to help multiple industry sectors meet the requirements of the new European regulations. It will also enable international manufacturers to reuse their security evaluation investments to demonstrate conformance to non-European regulations.”
The SESIP methodology is already mapped to other standards and regulations such as ETSI, (EN 303645 / TS 103732), ISO/IEC (62443-4-2), RED (EN 18031), UNECE WP.29 (ISO/SAE 21434) and NIST (NIST 8259 / NIST 8425). It is also being used by schemes such as PSA Certified, and standardization bodies including the Car Connectivity Consortium and the Wireless Power Consortium. In addition to Europe, SESIP is being adopted around the world in key markets such as China, where an agreement was recently reached between GlobalPlatform and China’s National Financial Technology Certification Center (NFTC).
GlobalPlatform has a number of initiatives in place to help accelerate SESIP adoption. A training program has been launched and available for any interested party. It has also launched the SESIP Adopters community to give non-members the ability to keep up to date with relevant technical documents and showcase certified SESIP products.
For more information on SESIP please visit: https://globalplatform.org/sesip/
About GlobalPlatform
GlobalPlatform is a technical standards organization that enables the efficient launch and management of innovative, secure-by-design digital services and devices, which deliver end-to-end security, privacy, simplicity, and convenience to users. It achieves this by providing standardized technologies and certifications that empower technology and service providers to develop, certify, deploy, and manage digital services and devices in line with their business, security, regulatory and data protection needs. GlobalPlatform technologies are used in billions of smart cards, smartphones, wearables and other connected and IoT devices.
GlobalPlatform standardized technologies and certifications are developed through effective industry-driven collaboration, led by multiple diverse member companies working in partnership with industry and regulatory bodies and other interested parties from around the world.
globalplatform.org | Twitter / X | LinkedIn | YouTube | GitHub | WeChat
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211681976/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release
Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom